Cresco Labs Inc. (OTCMKTS:CRLBF) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Cresco Labs Inc. (OTCMKTS:CRLBF) have been assigned an average rating of “Moderate Buy” from the eight brokerages that are presently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $2.50.

Several brokerages have weighed in on CRLBF. Roth Capital raised Cresco Labs to a “strong-buy” rating in a report on Sunday, November 10th. Atb Cap Markets lowered shares of Cresco Labs from a “strong-buy” rating to a “hold” rating in a report on Monday, December 9th. Finally, Cormark lowered shares of Cresco Labs from a “moderate buy” rating to a “hold” rating in a report on Monday, November 11th.

Cresco Labs Stock Down 2.8 %

OTCMKTS CRLBF opened at $0.94 on Tuesday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.39 and a current ratio of 1.97. Cresco Labs has a 52 week low of $0.78 and a 52 week high of $2.65. The stock has a market capitalization of $458.85 million, a P/E ratio of -4.70 and a beta of 1.79. The stock has a fifty day moving average of $1.08 and a 200-day moving average of $1.45.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.